{"schema_version":"secwatch.filing_event.v1","accession":"0001534120-26-000048","form_type":"8-K","ticker":"AVTX","cik":"0001534120","company_name":"Avalo Therapeutics, Inc.","filed_at":"2026-08-06T11:01:35+00:00","discovered_at":"2026-08-06T11:05:00.260856+00:00","generated_at":"2026-08-06T11:05:53.798683+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Avalo Therapeutics Q2 2026 net loss $36.4M; plans Phase 3 for abdakibart in HS in H1 2027","bullets":["Net loss of $36.4M for Q2 2026, up from $20.8M in Q2 2025; diluted EPS of ($0.83) vs ($1.92).","Cash, equivalents and investments of $472.2M as of June 30, 2026, expected to fund operations into 2029.","R&D expenses $23.4M, including $10.0M development milestone for abdakibart; G&A $8.1M.","Plans to initiate registrational Phase 3 program for abdakibart in hidradenitis suppurativa in H1 2027.","Expanded pipeline with AVTX-010 (anti-IL-1β antibody); IND submission planned for H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001534120-26-000048","json":"https://secwatch.observer/filing/0001534120-26-000048.json","markdown":"https://secwatch.observer/filing/0001534120-26-000048.md","text":"https://secwatch.observer/filing/0001534120-26-000048.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000048/0001534120-26-000048-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000153412026000048/avtx-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:05:53.798683+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}